System for monitoring the expression of transgenes
AssigneeMayo Foundation for Medical Education and Research
InventorsStephen James Russell, Kah Whye Peng
Life of this patent
Estimating the term…
Abstract
A novel strategy for monitoring the expression of a transgene in a patient is disclosed. A marker peptide is genetically fused to either the N-terminus or C-terminus of the product of a transgene through a linker peptide which bears the recognition sequence of a host cell protease. Expression of the transgene results in release of the marker peptide into extracellular body fluid of the patient in proportion to the amount of transgene product. The level of the released marker peptide serves as an indicator of the level of transgene expression. The system is particularly useful for monitoring the expression of therapeutic transgenes and production of the therapeutic gene product.
Claims39
A method of monitoring the production of a therapeutic polypeptide in a patient, said method comprising:
- (a) administering to said patient a nucleic acid construct encoding a therapeutic polypeptide and a marker polypeptide, wherein said marker polypeptide is releasable from a cell of said patient into an extracellular body fluid of said patient, wherein expression of said therapeutic polypeptide is regulated by a first promoter and expression of said marker polypeptide is regulated by a second promoter;
- and
- (b) detecting the presence or absence of said marker polypeptide above background in a sample of said extracellular body fluid, wherein the presence of said marker polypeptide above background in said sample is an indication that said therapeutic polypeptide is produced from said nucleic acid construct.
A method of monitoring the expression of a transgene in a patient, said method comprising:
- (a) introducing a nucleic acid construct into a cell in said patient, wherein said nucleic acid construct comprises a transgene and a sequence encoding a marker polypeptide, wherein said marker polypeptide is releasable from cells of said patient into an extracellular body fluid of said patient, and wherein expression of said transgene is regulated by a first promoter and expression of said sequence encoding said marker polypeptide is regulated by a second promoter;
- and
- (b) detecting the presence or absence of said marker polypeptide above background in a biological sample of said patient, wherein the presence of said marker polypeptide above background in said biological sample is an indication that said transgene is expressed in said patient.
A method of monitoring the expression of a transgene in a patient, said method comprising:
- (a) introducing a nucleic acid construct into a cell ex vivo, wherein said nucleic acid construct comprises a transgene and a sequence encoding a marker polypeptide, wherein expression of said transgene is regulated by a first promoter and expression of said sequence encoding said marker polypeptide is regulated by a second promoter;
- (b) introducing the cell of step (a) into said patient, wherein said marker polypeptide is releasable from cells of said patient into an extracellular body fluid of said patient;
- and (c) detecting the presence or absence of said marker polypeptide above background in a biological sample of said patient, wherein the presence of said marker polypeptide above background in said biological sample is an indication that said transgene is expressed in said patient.
Dependencies are inferred from the claim text.